<code id='0667EA525A'></code><style id='0667EA525A'></style>
    • <acronym id='0667EA525A'></acronym>
      <center id='0667EA525A'><center id='0667EA525A'><tfoot id='0667EA525A'></tfoot></center><abbr id='0667EA525A'><dir id='0667EA525A'><tfoot id='0667EA525A'></tfoot><noframes id='0667EA525A'>

    • <optgroup id='0667EA525A'><strike id='0667EA525A'><sup id='0667EA525A'></sup></strike><code id='0667EA525A'></code></optgroup>
        1. <b id='0667EA525A'><label id='0667EA525A'><select id='0667EA525A'><dt id='0667EA525A'><span id='0667EA525A'></span></dt></select></label></b><u id='0667EA525A'></u>
          <i id='0667EA525A'><strike id='0667EA525A'><tt id='0667EA525A'><pre id='0667EA525A'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:9121
          Monica Bertagnolli -- health policy coverage from STAT
          NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

          WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

          “It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

          advertisement

          But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

          AdobeAcadiaPharmaceuticalssaidMondaythatitsapprovedmedicinecalledNuplazidfailedtoimprovethesocialand